Category Archives: Medicine Wellness Health

Medicine Wellness Health

First patient treated in First-in-Man study of CoreMedic“s ChordArt™ mitral valve repair system

16 May 2018. Privately-held CoreMedic announces the start of a first-in-man „Chagall“ study to evaluate new minimally-invasive valve repair technology.

CoreMedic is developing ChordArt, a novel transfemoral chordal repair system to address unmet needs in the treatment of degenerative heart disease with mitral valve insufficiency, the most common valve pathology affecting more than 7 million patients worldwide. The ChordArt implant is used to replace the ruptured or elongated chordae of the valve and re-establishes the connection of the valve leaflets with the papillary muscle to restore the proper function. As ChordArt reduces the complexity of the procedure, both patients and physicians will benefit.

The „Chagall“ Trial is a prospective, multicenter, first-in-man study intended to establish the safety and effectiveness of the ChordArt System. The study was approved to enroll up to 40 subjects at up to 6 European centers. This study is the first trial of its kind to treat patients that have ruptured or elongated mi-tral chords with the ChordArt System.

The first-in-man (FIM) case using ChordArt was treated by the Heart Team led by Prof. Kstutis Ručinskas at the Vilnius Uni-versity Hospital, Lithuania. The ChordArt treatment was aimed at improving procedural outcomes and allowing standardized placement of the artificial chords with a dedicated, reproducible technique.

The patient recovered very well from the intervention and is continuously doing well. A 30 day follow-up showed no complications.

„Using the ChordArt reduced the invasiveness and duration of the procedure by repairing the valve in a fast, precise and safe way. This allowed the Heart Team to focus on the procedure and timing rather than manually placing the artificial chords to resolve the mitral insufficiency“ said Dr. Alberto Weber, Her-zzentrum Hirslanden, Zurich, Switzerland, who proctored the procedure. „Thanks to the ease of the ChordArt deployment technique, this was the fastest mitral valve chordal repair I have ever witnessed.“

For Thomas Bauer, CEO of CoreMedic, „The first clinical use of ChordArt is a major milestone in our path towards developing the best in class transfemoral mitral valve chordal repair system“. Hubertus Leonhardt, Managing Partner of medical device investor SHS, commented: „In 2017 we invested in CoreMedic to advance the development of ChordArt. We look forward to the results of clinical trials that will validate the applications of this breakthrough device.“

About Mitral Regurgitation:
Mitral valve regurgitation (MR) is a condition in which the mitral valve leaflets fail to close properly, allowing significant backflow of blood from the left ventricle into the left atrium during systole. Valve disease prevalence rises dramatically with age, reaching epidemic levels in the elderly.
MR is the most common valve pathology in the US. Over 7 million people suffer from the disease and each year 250,000 patients are diagnosed with MR. If untreated, MR can cause shortness of breath, decreased cardiac output, intolerance to physical exercise, congestive heart failure and death.
The standard-of-care in surgically treating degenerative MR involves replacing ruptured or elongated valve chordae with artificial implants to restore the function of the valve.
Implanting the standard artificial chordae requires complex and long procedural steps. This complexity is associated with risks including failure of the valve repair or the need to repeat the operation, the use of a cardiac bypass machine and stopping the heart.

About CoreMedic:
CoreMedic is dedicated to develop devices and therapies to dramatically improve the quality of life of patients with heart valve diseases, a primary challenge in global healthcare.
CoreMedic“s flagship product ChordArt is a transfemoral system for mitral valve chordal repair in the beating heart. ChordArt™ offers a first line therapy option for patients with mitral valve dysfunction and represents a less invasive procedure compared to the current surgical methods with open-chest or trans-apical access. ChordArt is designed to allow mitral repair in a wider patient population. ChordArt™ is currently under clinical evaluation in European clinics.
CoreMedic is a privately held medical device company headquartered in Radolfzell, Germany with a subsidiary in Biel/Bienne, Switzerland. CoreMedic is EN ISO 13485 certified.
The investor base consists of founders, private investors and medical device investor SHS Gesellschaft für Beteiligungsmanagement mbH ( www.shs-capital.eu).
For further information, please visit www.coremedic.ch

Company-Contact
CoreMedic GmbH
Thomas Bauer
Bismarckstrasse 12
72072 Tübingen
Phone: 089 20003038
E-Mail: info@coremedic.ch
Url: http://www.coremedic.ch

Press
IWK GmbH
Dr. Reinhard Saller
Ohmstr. 1
80802 München
Phone: 089 20003038
E-Mail: reinhard.saller@iwk-cp.com
Url: http://www.iwk-cp.com

Medicine Wellness Health

Full speed ahead – New Celsius42

The relaunch of Celsius42 GmbH is just a few days away

Full speed ahead - New Celsius42

Eschweiler 01.05.2018 – after 4 months and many hours of work by our creative team, we look forward to publishing our new company website in the near future.

„This innovation represents a true milestone for the development of Celsius42,“ says Christian Hartmann, the company“s new CEO. „In addition to the remake of our corporate identity, there are many ongoing activities associated with our product range,“ he adds. „We are currently working on our vision up to the year 2025. Our company will present many innovations and product enhancements at the MEDICA tradeshow in Düsseldorf this year and over the course of the coming years.“

Parallel to product and market development, the company“s priorities for the coming months and years naturally also include global expansion. Moreover, technical and scientific cooperation will be at the core of this growth strategy.

We invite you to visit us at ESHO in Berlin from May 16-19 to learn more about our innovations in direct conversations. We look forward to your visit. Our communication channels will keep you updated about the further activities of our company.

Your Celsius42 Team

Who we are.

The people working at Celsius42 have one shared goal – to be united in the fight against cancer. To pool knowledge. To leverage partners and resources. To explore increasingly intelligent pathways in medical technology to finally win the fight. Medicine has fought this battle for a long time. A battle against a clever opponent: cancer. Hyperthermia is the active principle of Celsius42 products. Targeted
thermal energy that causes stress in cancer cells. It has many positive effects in chemotherapy or radiation therapy, but also strengthens the immune system.

The people at Celsius42 know that they are on
the right track. Their tenacity, energy and human experience make them a tight-knit team. With a single mission: to develop innovative hyperthermia products that help to fight cancer gently but effectively.

That is Celsius42. That is TCS – Tumor Cell Solution.

Contact
Celsius42 GmbH
Christian Hartmann
Hermann-Hollerith-Straße 11
52249 Eschweiler
Phone: +49 2403 7829 230
E-Mail: info@celsius42.de
Url: http://www.celsius42.de

Medicine Wellness Health

Alzheimer’s disease: Patients benefit from nuclear imaging

(Vienna, 19 April 2018) With the help of Positron emission tomography (PET) Alzheimer“s disease (AD) can be detected long before the onset of the symptoms by making beta-amyloid in the brain visible. However, since there is still no cure for AD the question has been raised if such a diagnosis is really beneficial for the patient or rather more of a burden. First results of a large study, currently under way, show that PET diagnosis helped to improve medical management and counseling in over 65% of the patients. „AD patients clearly benefit from nuclear imaging,“ says Dr. Valentina Garibotto, expert of the European Association of Nuclear Medicine (EANM).

Alzheimer“s disease is the most frequent cause of dementia and one of the most important causes of disability in the elderly. The condition induces a decline in mental ability that usually develops and progresses slowly. Memory and judgment are impaired, and personality may deteriorate. The target of the PET examination is beta-amyloid, which is the chief component of plaques that are one of the hallmarks of Alzheimer“s. Recently developed tracers (radioactively labelled substances the patient is injected with) make these plaques visible on the computer screen. By applying this method the likelihood of Alzheimer“s disease can be established in patients with a higher degree of certainty, as compared with other routine diagnostic tools.

PET exams improve health care management
While its accuracy is uncontroversial the benefit of nuclear imaging for AD patients has frequently been questioned: Since there is no cure for this disease the gained diagnostic knowledge might be considered not only useless but an unnecessary psychological burden for the patient while he is still fit. In order to clarify this matter and to examine the actual impact of PET procedures on AD patient care and health outcome two large studies are currently under way: The IDEAS study (Imaging Dementia-Evidence for Amyloid Scanning) in the USA (www.ideas-study.org) and the AMYPAD study (Amyloid Imaging to prevent AD) in Europe (amypad.eu).

IDEAS started in 2016 and includes 18.000 participants. First results show that the outcome of PET scans have concrete beneficial consequences: They led to a change in medical and general health care management in around 65% of the patients. These changes consisted among other things in different drug prescriptions, making use of the fact that amyloid imaging allows doctors to determine with high accuracy whether in patients with mild symptoms Alzheimer“s is the cause or whether it can be excluded, so that some other kind of dementia or another condition has to be taken into account. Thus, depending on the PET exam results doctors changed to drugs specific for Alzheimer (namely aceltycholinesterase inhibitors) or they reversely abandoned these drugs in favor of a better suited medication, for exampleantidepressants or antipsychotics. PET scan results in favor of AD also induced an appropriate counseling about safety and future planning, thus helping patients and their friends and family to avoid preventable risks. For example, a diabetic who is also diagnosed with AD would not be left alone any longer to manage his insuline doses. „These interim results already provide convincing evidence that AD patients benefit largely from a more accurate diagnosis and we expect further study outcomes to complete the picture,“ says Dr. Valentina Garibotto of the EANM Neuroimaging Committee.

Nuclear imaging pivotal in AD research
Further important insights are to be expected of the AMYPAD study which has just started. This is a collaborative research initiative and part of the European Innovative Medicines Initiative (IMI). The overall goal of the program is to determine the value of amyloid PET imaging to diagnose and guide treatment, namely clinical trials, in AD. „Despite the hitherto unsatisfying results of therapeutic trials, our knowledge and understanding of AD has dramatically evolved over the last decades and PET imaging has played and still plays an increasingly central role. Accordingly, the next EANM focus meeting will be fully dedicated to the field of neuroimaging in AD. Entitled „Molecular Imaging of Dementia – The future is here“ it will invite worldwide experts to update the community on the latest developments,“says Dr. Garibotto.

www.whatisnuclearmedicine.com
www.eanm.org

Presseagentur für Medizinthemen

Contact
impressum health & science communication
Frank von Spee
Hohe Brücke 1
20459 Hamburg
Phone: 040 31786410
E-Mail: vonspee@impressum.de
Url: http://www.impressum.de

Medicine Wellness Health

LEONARDO® DUAL by biolitec®: First medical laser for multifunctional applications in minimally invasive therapies

LEONARDO® laser family first universally applicable medical laser system with a combination of two wavelengths for use in several disciplines

LEONARDO® DUAL by biolitec®: First medical laser for multifunctional applications in minimally invasive therapies

biolitec® LEONARDO® DUAL lasers family (Source: biolitec biomedical technology GmbH)

Jena, April 19th, 2018 – The unique medical laser system LEONARDO® DUAL consists of lasers with 45 watt, 100 watt and 200 watt power ranges. These lasers are the most versatile medical lasers available for medical la-ser treatments, offering a variety of tissue interactions – for open and for endoscopic procedures with contact or non-contact delivery options. The possibility to use two wavelengths in one compact, mobile and space-saving laser system constitutes a clear benefit for the user, just as the multidisciplinary use of the lasers and the low-maintenance. Each wavelength can be individually selected or blended together to offer the desired tissue effects, such as incision, excision, vaporization, hemostasis and coagulation of soft tissue. All of the lasers are equipped with the two wavelengths of 980 nm and 1470 nm, which can be continuously used during the treatment.

The new LEONARDO® DUAL series lasers are suitable for minimally invasive procedures in phlebology, proctology, urology, gynecology, orthopedics, thoracic surgery, pneumology, ENT and aesthetic surgery. As the lasers feature not only a wavelength of 980 nm but also of 1470 nm, they are also ideally suited for the use in phlebology. The laser procedure with a wavelength of 1470 nm minimizes any post-operative inflammatory pain and bruising, due to a 400 times greater absorption coefficient in water compared to 810 nm lasers targeting hemoglobin. In addition, an easy-to-use system for a significantly improved treatment outcome is provided by means of the radial (360°) emission of the patented ELVeS® Radial® 2ring fiber.

The ELVeS® Radial® 2ring fiber splits the energy in two phases, which leads to an effective closure of the vein. By avoiding perforation of the vein wall and associated thermal irritation of the surrounding tissue, post-operative pain is minimized. The ELVeS® Radial® 2ring slim fiber was especially designed for the treatment of superficial venous reflux on perforator veins and small saphenous veins.

With the biolitec® therapies FiLaC® (Fistula-tract Laser Closure for anal fistulae), SiLaC (Sinus Pilonidalis treatment) and LHP® (LaserHemorrhoidoPlasty for hemorrhoids) for proctology, biolitec® introduced a new innovative minimally invasive method, where the diseased tissue is irradiated from the inside with the laser energy and thus gently destroyed.

Also part of the family and suitable for varicose vein treatment is the LEONARDO® Mini 1470 nm. Weighing only 900 grams, this device can be used mobile in the established treatment methods of biolitec® for venous diseases and other medical treatments. Besides the lasers, biolitec® provides a wide range of accessories and offers suitable fibers with specific characteristics that are perfectly coordinated with versatile therapeutic areas and the respective application, due to continuous research and development.

If you are interested in presentations or congresses on the subject of minimally invasive medical laser therapies by biolitec®, please have a look at our website www.biolitec.com (section Company/Events).

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

Digital Health Market Worth 378 Billion by 2024

Digital Health Industry Outlook & Forecast.

Digital Health Market Worth 378 Billion by 2024

Digital Health Industry Outlook & Forecast

MarketStudyReport.com Adds a New „Digital Health market research report for the period of 2017 – 2024 to its research database covering information and data by Telehealth, by mHealth, by Health Analytics, by Digital Health Systems, industry analysis report, regional outlook, growth potential, price trends, competitive market share & forecast spreading across 240 Pages with table and figures in it.

Digital Health Market will exceed USD 378 billion by 2024. Growing investment by venture capitalists and favorable government initiatives will drive digital health market over the forecast years. Escalating demand for digitization in healthcare sector along with advents in technology including Healthcare Bots, mHealth are factors fueling industry growth.

Request a sample copy of this research: https://www.marketstudyreport.com/request-a-sample/467853/?utm_source=prgateway-CC

Healthcare Bots include chatbots that allows patient access for health concerns and provides support from doctors and nurses. Such advanced innovative technology further propels industry growth.

Revolution in field of rehabilitation by digital health technology through integration of technology with robotics is anticipated to render immense scope for business growth. For instance, in January 2017, VisioMed Group announced partnership with Robotopi that aimed at enhancing the life assistant Pepper by BewellConnect medical devices and health services will stimulate market growth.

Security concerns pertaining patient data will hinder digital health market growth. Apart from this, high cost maintenance and installation of hardware, IT upgrades, and systems for comprehensive enterprise adoption will hamper industry expansion.

Digital health system business segment accounted for largest market share on an account of high demand for digital health systems coupled with rise in adoption of digital health systems. Growing use of healthcare informatics technologies such as Electronic Health Record (EHR) and Radiology Information System (RIS) will further boost industry growth.

In North American region, U.S. digital health market held largest share in 2016 and is most likely to hold the commanding position in foreseeable future. The growth is attributable to highly developed healthcare IT infrastructure, coupled with government initiatives for implementing digital health technologies in healthcare setup.

UK digital health market should witness lucrative growth in coming years owing to growing initiatives for remote monitoring, patient engagement, telemedicine, health analytics and Big Data. Central government programs for telecare and early adoption of telecare service are paving paths for business growth.

Get a discount on this premium research report: https://www.marketstudyreport.com/check-for-discount/467853/?utm_source=prgateway-CC

Japan digital health market will grow significantly due to increasing use of devices equipped with telehealth technology and mobile health. Growing demand for digital health and escalating initiatives to integrate digital technologies in healthcare setup will further boost market growth.

Some of the prominent business players are Allscripts Healthcare Solutions, AT & T, Athenahealth, Biotelemetry, Cerner, Cisco Systems, eClinicalWorks, iHealth Lab, Koninklijke Philips N.V., LifeWatch, McKesson, and Qualcomm.

Industry players are capitalizing on innovative research for development of advanced digital health systems. Growing investment in technology enhancement is projected to propel industry growth. Business players are focusing on partnerships and acquisitions for enhancing their position in industry.

Related Report:

On a related matter, another research has been added to the database of Market Study Report providing the information on „Healthcare 3D Printing Market“. According to the report, Healthcare 3D Printing Market size is set to exceed USD 2.2 billion by 2024 driven by Increasing number of surgeries and rising demand for personalized medical care.

UK healthcare 3D printing market will grow at over 20% CAGR by 2024 owing to the increasing awareness through conference and discussion on effective solutions for the medical field. Growing R&D focus on advances in 3D printing devices should further stimulate business growth.

Some of the companies operating in healthcare 3D printing market include Organovo Holding, Stratasys, 3D Systems, Reninshaw, Aspect Biosystems, Bio3D Technologies, Cyfuse Biomedical, 3Dynamics Systems, Envision TEC and Materialise. The industry players are engaged in strategic mergers and acquisitions, collaborations coupled with new product launch and innovation to gain competitive market share.

Read Full Report Description: https://www.marketstudyreport.com/reports/healthcare-3d-printing-market/?utm_source=prgateway-cc

About Us:

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.

Contact Us:
Market Study Report
The Green Suite #4594,
Dover, DE 19901
United States
Phone: 1-201-355-0868
US Toll Free: 1-866-764-2150
Email:sales@marketstudyreport.com
Website: https://www.marketstudyreport.com

Contact
Market Study Report
Arun Hegde
North Main Street, 4
19975 Selbyville
Phone: 1-866-764-2150
E-Mail: Sales@marketstudyreport.com
Url: http://marketstudyreport.com

Medicine Wellness Health

Brussels, May 23: Scientific Conference epiXchange2018

Seven large EU-funded projects have joined forces – epiXchange 2018 brings together Europe’s best brains to pave the way for future epilepsy research.

Brussels, May 23: Scientific Conference epiXchange2018

Scientific Conference epiXchange 2018, May 23, 2018, Brussels

Around 50 million people worldwide suffer from epilepsy, making it one of the most common neurological diseases. To decrease this figure and pave the way for future ground-breaking epilepsy research, seven large EU-funded projects have joined forces. epiXchange 2018 is a unique global community building event, designed to gather a critical mass of epilepsy researchers to exchange about latest progress in research aiming to improve the way epilepsy is diagnosed and treated and thereby increase the quality of life of affected people. Six of these projects were funded through the 7th Framework Programme (FP7) which provided total funding of EUR 52 million.

Despite a great progress in the management of epilepsy, 30-40% of epilepsy patients are refractory to all available medications.
Moreover, about 50% of children with epilepsy suffer from epilepsy-related co-morbidities, including developmental delay, learning disabilities, and autism spectrum disorder. Diagnostics is another issue.
„Diagnosis of epilepsy is really difficult,“ explained Prof. David Henshall, coordinator of the epiXchange 2018 co-organising EpimiRNA project. „Seizures are the main clinical symptom for the disease but it is very rare that a doctor will witness the patient having a seizure.“

New innovative solutions to diagnose and treat epilepsy

As published in HORIZON – The EU Research & Innovation Magazine on February 12, one of the major results from the epiXchange projects is the development of biomarkers for epilepsy diagnosis. Identifying biomarkers and changes to brain structures may ultimately lead to new treatments.
„Combining biomarkers is key,“ said Prof. Merab Kokaia, coordinator of the co-organising EPITARGET project. „It could make treatment more personalised in the years to come. Another interesting result as published in HORIZON on April 6 is the fact that delaying epilepsy onset through preventive medication in children with related disorders could reduce the impact on development of epilepsy and other related symptoms.
„If you have a brain malformation… there is nothing you can do to revers it. But… if you can prevent epilepsy from aggravating the situation you can improve the clinical status of these patients“, said Renzo Guerrini, coordinator of the co-organising DESIRE project.
Efforts have been made to pin down the genetics behind the disorders. Blood samples of babies at four key moments – at birth, when the EEG first begins to pick up problems, when seizures begin and at two years of age may help us to develop new drugs.
„We have a very, very unique situation. For the first time we have access to the molecular story before epilepsy“, said Prof. Sergiusz Jozwiak, coordinator of the co-organising EPISTOP project.

These findings and many others will be showcased at epiXchange. To boost the impact of the event, the epiXchange partners are preparing a white paper, presenting the current state of the art in epilepsy research, major bottlenecks and recommendations to shape the way for further research breakthroughs, to move forward to new ways of treatment and to bring research results closer to clinical application.

Five major areas

The epiXchange 2018 scientific conference focuses on five major themes in epilepsy research:

Genetics:
Development of novel treatment strategies based on optogenetics, gene and stem cell therapies.

Therapeutics:
Development of effective epileptogenic therapeutics, many of which face different kinds of bottlenecks e.g. regulatory hurdles.

Biomarkers:
Identification of new biomarkers in blood, peripheral organs, brain tissue, electrophysical data, behavioural data and imaging data, in order to develop novel preventive strategies in at-risk patients.

Biobanks and databases:
Integration of Biobanks and databases into clinical care to facilitate preclinical research. A collaborative approach as foundation for the future of epilepsy research and other disease model biobanks.

Co-morbidities:
Exploration of the mechanisms underlying bi-directional relations between epilepsy and neurological co-morbidities to reduce the high burden of co-morbidities in epilepsy.

epiXchange 2018 is is a dissemination activity of the FP7 funded projects DESIRE, EpimiRNA, EpiTarget and EPISTOP and is open for scientists, EC representatives, industries and other stakeholders from the epilepsy community as well as the press.

epiXchange 2018 key data
Organisers: DESIRE, EpimiRNA, EPISTOP and EpiTarget; Scientific contributions by EpiCare, EpiPGX and Epixchange
Venue: THE EGG, Brussels, www.theeggbrussels.com
Date: May 23, 2018
Homepage: www.epiXchange2018.eu
Twitter: www.twitter.com/epiXchange
Facebook: www.facebook.com/epiXchange2018/

Seven large EC-funded projects on epilepsy co-organise this conference to disseminate project results and discuss the future of epilepsy research in the EU and worldwide.

Six of these projects were funded through the 7th Framework Programme (FP7) which provided total funding of EUR 52 million.

Four of the projects (DESIRE, EpimiRNA, EPISTOP and EpiTarget), still ongoing FP7 collaborative research projects, are co-financing the event. Scientific contributions are provided by partners from EpiCare, an ongoing reference network project, as well as EpiPGX (FP7 collaborative research project) and Epixchange (FP7 MSCA ITN project), which are now finished.

Contact
ARTTIC S.A.S
Sebastian Vinzenz Gfäller
Oskar-von-Miller-Ring 29
80333 München
Phone: +49-89 248 83 03 -36
E-Mail: gfaeller@arttic.eu
Url: http://www.arttic.eu

Medicine Wellness Health

Global Ready To Drink Tea And Coffee Market Status and Prospect, Forecast 2018 to 2026

Global Ready To Drink Tea And Coffee Market Status and Prospect, Forecast 2018 to 2026

„Ready to drink“ (RTD) refers to packaged beverages that are ready for consumption by individuals and available in various retail stores off-the-shelf. Ready-to-drink beverages can be immediately consumed upon purchase, unlike that of traditional beverage mixes, powders, or brew-it-yourself tea or coffee products. Bottled or canned ice tea, coffee, smoothies, energy drinks, and alcopops (ready-made alcohol cocktails) are some examples of RTD beverages. Ready to drink tea and coffee products, along with alcopops are the most widely consumed ready to drink beverage products in the market.

Continuously changing lifestyle, increasing disposable income, and rising demand for healthier alternatives to carbonated drinks are key factors driving growth of the global ready to drink tea and coffee market. In addition, increasing consumer preference for ready to drink (RTD) beverages, especially RTD iced tea being perceived as a healthier beverage among the general population, and ready to drink coffee considered as an energy booster drink. This is a major factor expected to boost demand for RTD tea and coffee market over the forecast period.

Lack of appropriate infrastructure in developing economies for storage and sale of ready to drink beverage products is a key factor expected to restrain growth of the global ready to drink tea and coffee market. Additionally, fluctuating costs of raw materials, coupled with problems related to consumption of ready to drink beverage products are other factors anticipated to hamper growth of the global ready to drink tea and coffee market over the forecast period.

The global ready to drink tea and coffee market report has been segmented on the basis of additives, packaging, price, distribution channel, and region. On the basis of region, the global ready to drink tea and coffee market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Do Inquiry of the Report Here: https://marketresearch.biz/report/ready-drink-tea-coffee-market/#inquiry

Currently, the market in Asia Pacific dominates the global ready to drink tea and coffee market in revenue terms owing to high adoption of ready to drink tea and coffee products, changing lifestyle, and high disposable income in countries in the region. The market in North America accounted for second-highest revenue share in the global ready to drink tea and coffee market, due to rising demand for ready to drink tea and coffee products, and high disposable income, followed by markets in Europe, Latin America, and Middle East & Africa respectively. The markets in Europe and Latin America are also projected to show significant growth over the forecast period.

Prominent players in the global ready to drink tea and coffee market include PepsiCo Inc., The Coca-Cola Company, Suntory Holdings Ltd., Nestle S.A., Ting Hsin International Group, Sapparo Beverage Co. Ltd., Unilever NV, Uni-President Enterprises, Starbucks Corporation, and Arizona Beverage Company.

Prudour Pvt. Ltd. ( https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions.

Contact
MarketResearch.Biz
Krutika Bhoot
Prudour Pvt. Ltd. 420 Lexington Avenue, Suite 300 NY
10170 New York City
Phone: +1 347 826 1876
E-Mail: krutika@marketresearch.biz
Url: https://marketresearch.biz/

Medicine Wellness Health

Global Implantable Drug Delivery Devices Market Status and Prospect, Forecast 2018 to 2026

Global Implantable Drug Delivery Devices Market Status and Prospect, Forecast 2018 to 2026

Implantable drug delivery devices have several advantages over conventional oral or parenteral dosage forms as it allows site specific administration where the drug is needed the most, also it allows significantly lower dosing of drug which in turn minimize potential side effects. Furthermore, it allows sustained release of therapeutic agent whereas enhances efficacy of treatment.
Implantable drug delivery devices are generally less burdensome than pills and injections. Moreover, market players are developing biodegradable stents that are naturally-dissolving as it does not require additional surgery for removal of device.

Growing incidence of chronic disease such as cardiovascular diseases, diabetic retinopathy is expected to drive the growth of implantable drug delivery devices market. Moreover, increasing number of collaborations between pharmaceutical companies and technical provider are other factors anticipated to further drive growth of the global implantable drug delivery devices market over the forecast period.

However, device failure and cost associated with the use of device are major factor restraining growth of the global implantable drug delivery devices market.

Technological advancements and innovations focusing on development of safe, efficient and biodegradable devices is expected to create new opportunities for major players in the global implantable drug delivery devices market over the forecast period.
The global implantable drug delivery devices market report has been segmented on the basis of product type, technology, application, and region. On the basis of region, the global implantable drug delivery devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Do Inquiry of the Report Here: https://marketresearch.biz/report/implantable-drug-delivery-devices-market/#inquiry

North America market dominates the global implantable drug delivery devices market in terms of revenue contribution as compared to that of markets in other regions. This is attributed by new product approval by US FDA, owing to the huge patient pool and awareness about the application in the region. Europe accounts for second-largest revenue share contribution to the global implantable drug delivery devices market, followed by markets in Latin America, Asia Pacific, and Middle East & Africa respectively.The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to the rapid adoption of implantable drug delivery devices and efficiency in birth control.

Some prominent players in the global implantable drug delivery devices market are Merck & Co., Inc., Allergan, Inc., Bausch & Lomb Inc., Abbott Laboratories, Bayer AG, Psivida Corp, Medtronic Plc., Arrow International, Boston Scientific Corporation, and Theragenics Corporation.

Prudour Pvt. Ltd. ( https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions.

Contact
MarketResearch.Biz
Krutika Bhoot
Prudour Pvt. Ltd. 420 Lexington Avenue, Suite 300 NY
10170 New York City
Phone: +1 347 826 1876
E-Mail: krutika@marketresearch.biz
Url: https://marketresearch.biz/

Medicine Wellness Health

Global Dosing Systems Market Status and Prospect, Forecast 2018 to 2026

Global Dosing Systems Market Status and Prospect, Forecast 2018 to 2026

Dosing systems are commonly used to inject fluids or chemicals in large or small quantity in production & processing, and is used in various processing and manufacturing industries such as textile, thermal power stations, oil & gas, water treatment, food & beverages, pharmaceuticals, paper & pulp, chemical processes, etc. Dosing systems are designed with high accuracy, and it ensures high safety, and security measures, longer service life, and excellent performance.

Increasing importance of wastewater treatment by national governments, and increase in production rate of pharmaceuticals and chemical processing industries are key factors driving growth of the global dosing systems market over the forecast period. In addition, increasing preference for dosing systems, owing to factors such as faster outputs, impart precision, and effectiveness are expected to fuels growth of the global dosing systems market. Moreover, increasing consumer awareness, and technological advancement with chemical processing industries are expected to further fuel growth of the global dosing systems market over the forecast period.

However, high cost of raw materials, and increasing number of coal bed methane reserves are key factors restraining growth of the global dosing systems market over the forecast period. In addition, issues related to lack of greenfield investments is another factor expected to hamper growth of the global dosing systems market in the near future.

Moreover, increasing trend towards automation, innovation, and increasing number of software in these systems are expected to spur demand for dosing systems during the forecast period.

Do Inquiry of the Report Here: https://marketresearch.biz/report/dosing-systems-market/#inquiry

The market in North America dominates the global dosing systems market in terms of revenue, owing to rapidly growing industrial sectors, followed by Europe respectively. The market in Asia Pacific is expected to witness highest growth in terms of revenue during the forecast period owing to presence of manufacturing facilities of large chemical, food & beverages, paper & pulp, and pharmaceutical companies in countries in this region.

Key players in the global dosing systems market include GRUNDFOS GMBH, IDEX Corporation, ProMinent GmbH, Seko S.p.A., EMEC S.r.l., Gee & Company (Effluent Control & Recovery) Limited, LEWA GmbH, and NETZSCH Pumpen & Systeme GmbH, Blue-White Industries, Ltd., and SPX Corporation.

Prudour Pvt. Ltd. ( https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions.

Contact
MarketResearch.Biz
Krutika Bhoot
Prudour Pvt. Ltd. 420 Lexington Avenue, Suite 300 NY
10170 New York City
Phone: +1 347 826 1876
E-Mail: krutika@marketresearch.biz
Url: https://marketresearch.biz/

Medicine Wellness Health

Global Protein Hydrolysis Enzymes Market Status and Prospect, Forecast 2018 to 2026

Global Protein Hydrolysis Enzymes Market Status and Prospect, Forecast 2018 to 2026

The specialty enzymes prepared from protein hydrolysis procedure are known as protein hydrolysis enzymes. It has animal-based proteases such as trypsin, plant based proteases such as papain and a large variety of microbial source proteases.

Rising demand for protein hydrolysis enzymes from various end-use industries such as pharmaceuticals, and animal feed is a key factor driving growth of the global protein hydrolysis enzymes market. In addition, increasing adoption of protein hydrolysis enzymes in detergent and textile manufacturing is another leading factor anticipated to fuel growth to the global protein hydrolysis enzymes market over the forecast period. Also, rising adoption rate of protease enzymes into amino acids owing to applications such as hydrolysis of protein peptides, and controlling nitrogen content and phosphorus pollution are other factors expected to support growth of the global protein hydrolysis enzymes market.

However, availability of substitute chemicals, and shelf life related issues are some key factors restraining growth of the global protein hydrolysis enzymes market. In addition, high salt concentration and formation of unacceptable components is another factor expected to hamper growth of the global protein hydrolysis enzymes market over the forecast period.

The global protein hydrolysis enzymes market report has been segmented on the basis of source, application, and region. On the basis of region, the global protein hydrolysis enzymes market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Do Inquiry of the Report Here: https://marketresearch.biz/report/protein-hydrolysis-enzymes-market/#inquiry

The market in North America is expected to dominate the global protein hydrolysis enzymes market and expected to account for highest market share in terms of revenue owing to increasing demand for global protein hydrolysis enzymes market in animal feed and detergent industries in countries in the region. The market in Europe expected to account for the second-highest revenue share contribution to the protein hydrolysis enzymes market followed by markets in Asia Pacific, Latin America, and Middle East & Africa respectively. The market in Asia Pacific is projected to witness fastest growth in terms of revenue, owing to increasing demand for hydrolysis enzymes from pharmaceutical and textile industry in countries in the region.

Prominent players in the global protein hydrolysis enzymes market include Koninklijke DSM N.V., Novozymes A/S, AB Enzymes GmbH, Dyadic International, Inc., Specialty Enzymes & Biotechnologies Co., E.I. Dupont De Nemours & Company, Jiangsu Boli Bioproducts Co., Ltd., and Amano Enzyme Inc.

Prudour Pvt. Ltd. ( https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions.

Contact
MarketResearch.Biz
Krutika Bhoot
Prudour Pvt. Ltd. 420 Lexington Avenue, Suite 300 NY
10170 New York City
Phone: +1 347 826 1876
E-Mail: krutika@marketresearch.biz
Url: https://marketresearch.biz/